コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 a strategy to improve safety and efficacy of therapeutic angiogenesis.
2 ological clinical conditions has been called therapeutic angiogenesis.
3 first growth factors to be tested for use in therapeutic angiogenesis.
4 ffect of progenitor cell transplantation for therapeutic angiogenesis.
5 e strategy to robustly boost the efficacy of therapeutic angiogenesis.
6 blood vessels is critical for the success of therapeutic angiogenesis.
7 This hypothesis was tested in the context of therapeutic angiogenesis.
8 cell therapy have moved to the forefront of therapeutic angiogenesis.
9 as emerged as one of principal approaches to therapeutic angiogenesis.
10 ulating interest in their ability to mediate therapeutic angiogenesis.
11 indings suggest a potential role for PEMF in therapeutic angiogenesis.
12 cacy of revascularization strategies such as therapeutic angiogenesis.
13 y provide a noninvasive method for assessing therapeutic angiogenesis.
14 healing, and which is a potential target for therapeutic angiogenesis.
15 r to avoid the formation of leaky vessels in therapeutic angiogenesis.
16 us angiogenic factors, might provide optimal therapeutic angiogenesis.
17 provide a more effective strategy to achieve therapeutic angiogenesis.
18 is system was investigated in the context of therapeutic angiogenesis.
19 endothelial cell mitogen designed to promote therapeutic angiogenesis.
20 sues is a potential cause for the failure of therapeutic angiogenesis.
21 chnique may be useful in clinical studies of therapeutic angiogenesis.
22 gs are consistent with a favorable effect of therapeutic angiogenesis.
23 importance of regulating VEGF expression for therapeutic angiogenesis.
24 lone or in combination with VEGF, to promote therapeutic angiogenesis.
25 osis and vein graft intimal hyperplasia, and therapeutic angiogenesis.
28 ser revascularization (TMR) for induction of therapeutic angiogenesis and arteriogenesis in the chron
30 nd mouse, which gives insight of VEGF165b in therapeutic angiogenesis and VEGF distribution in human
31 ollateral vessel growth to ischemic tissues (therapeutic angiogenesis) and for delivering anti- or pr
32 endothelial growth factor (VEGF) to promote therapeutic angiogenesis are under consideration for con
35 ings of TRAFFIC provide evidence of clinical therapeutic angiogenesis by intra-arterial infusion of a
36 he recently reported approaches to stimulate therapeutic angiogenesis by recreating the embryonic vas
37 CD34Exo-mediated ischemic tissue repair and therapeutic angiogenesis by studying their miRNA content
43 ngiogenesis 30 days later showed evidence of therapeutic angiogenesis for both pcVEGF-C and rhVEGF-C.
46 s angiogenesis in two animal models in which therapeutic angiogenesis has been characterized as a com
47 To address this unmet need, the science of therapeutic angiogenesis has been evolving for almost tw
56 repancy exists between the potent effects of therapeutic angiogenesis in laboratory animals and the m
58 dothelial growth factor (VEGF) treatment for therapeutic angiogenesis in myocardial ischemia, we expl
59 In addition, preliminary results on use of therapeutic angiogenesis in patients with Buerger's dise
60 t an alternative to VEGF-A for strategies of therapeutic angiogenesis in patients with limb and/or my
61 overexpression of VEGF sufficient to induce therapeutic angiogenesis in selected patients with criti
62 but the impact of endothelial dysfunction on therapeutic angiogenesis in the myocardium has been uncl
63 (VEGF) 121 cDNA (Ad(GV)VEGF121.10) to induce therapeutic angiogenesis in the myocardium of individual
64 ssue regeneration, supporting the concept of therapeutic angiogenesis in tissue-engineering strategie
65 firm the feasibility of a novel approach for therapeutic angiogenesis in which neovascularization may
66 ction that tumor ischemia should result from therapeutic angiogenesis inhibition, tumor cell hypoxia
67 D 173074 is thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the tre
74 mic tissues using angiogenic growth factors (therapeutic angiogenesis) is a an exciting frontier of c
75 ong-term constitutive expression of VEGF for therapeutic angiogenesis may be limited by the growth of
78 have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and there
84 nt of collateral arteries, a concept called "therapeutic angiogenesis." The objectives of this phase
85 Gene transfer is a novel means of providing therapeutic angiogenesis: the cDNA coding for specific a
86 hat (1) autophagy is essential for effective therapeutic angiogenesis to treat CAD and MI; (2) AGGF1
87 duration of gene expression investigated for therapeutic angiogenesis transfer have been unassociated
89 lying mechanisms involved in physiologic and therapeutic angiogenesis, underscoring the relative impo
90 nical stage, experimental data indicate that therapeutic angiogenesis using short-term gene expressio
91 vascular endothelial growth factor (VEGF) in therapeutic angiogenesis was suggested by experiments in
92 rdial perfusion; however, further studies of therapeutic angiogenesis with Ad5FGF-4 will be necessary
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。